文献速递前列腺癌

前列腺癌肿瘤-only测序后的基于基因的确证性胚系检测

Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
PubMed 文献 · Eur Urol · 2022-09-15

研究评估了2015年1月1日至2020年1月31日在纪念斯隆凯特琳癌症中心接受肿瘤和胚系测序的前列腺癌男性,分析60个癌症易感基因中致病性变异。1883例中1084例(58%)有体细胞或胚系致病性变异,其中240例(22%)有至少一个胚系变异;不同基因的胚系概率差异很大,最高为PALB2(69%)、MITF(62%)、HOXB13(60%)、CHEK2(55%)、BRCA1(55%)和BRCA2(47%),任何DNA损伤修复基因变异的总体胚系概率为40%。

要点

  • 肿瘤-only测序中发现的致病性变异,22%为临床可操作的胚系变异。
  • TP53、PTEN或RB1变异在746例(40%)患者中识别,且均为体细胞性。
  • 不同基因胚系概率差异大,PALB2最高69%,BRCA2为47%,任何DNA损伤修复基因总体为40%。

核心结论

  • 在肿瘤测序发现致病性变异的前列腺癌患者中,22%具有临床可操作的胚系变异,其胚系概率因基因而异。
  • 研究结果提供了基于证据的临床框架,用于在肿瘤-only测序后优先转诊遗传咨询。

研究设计与样本

  • 研究纳入2015年1月1日至2020年1月31日在纪念斯隆凯特琳癌症中心接受肿瘤和胚系测序的前列腺癌男性。
  • 分析60个中或高外显率癌症易感基因中的致病性和可能致病性变异,并计算每个基因变异的胚系概率(胚系/胚系+体细胞)。

主要发现

  • 1883例患者中,1084例(58%)在60个癌症易感基因之一具有体细胞或胚系致病性变异,其中240例(22%)具有至少一个胚系变异。
  • 最常见的变异位于TP53、PTEN、APC、BRCA2、RB1、ATM和CHEK2。
  • TP53、PTEN或RB1变异在746例(40%)患者中识别,且均为体细胞性。
  • 胚系概率最高的变异位于PALB2(69%)、MITF(62%)、HOXB13(60%)、CHEK2(55%)、BRCA1(55%)和BRCA2(47%),任何DNA损伤修复基因变异的总体胚系概率为40%。

关键数值与推荐

  • TP53、PTEN或RB1变异在746例(40%)患者中识别,且均为体细胞性。
  • 胚系概率:PALB2 69%、MITF 62%、HOXB13 60%、CHEK2 55%、BRCA1 55%、BRCA2 47%。
  • 任何DNA损伤修复基因变异的总体胚系概率为40%。

临床怎么用

  • 作者认为,肿瘤-only测序后可根据基因的胚系概率优先转诊遗传咨询。
  • 作者指出,肿瘤测序发现致病性变异的患者中22%具有临床可操作的胚系变异。

局限性

  • 大多数纳入队列的男性患有转移性疾病。
  • 体细胞和胚系变异存在不同的致病性阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor-only genomic profiling is an important tool in therapeutic management of men with prostate cancer. Since clinically actionable germline variants may be reflected in tumor profiling, it is critical to identify which variants have a higher risk of being germline in origin to better counsel patients and prioritize genetic testing. OBJECTIVE: To determine when variants found on tumor-only sequencing of prostate cancers should prompt confirmatory germline testing. DESIGN, SETTING, AND PARTICIPANTS: Men with prostate cancer who underwent both tumor and germline sequencing at Memorial Sloan Kettering Cancer Center from January 1, 2015 to January 31, 2020 were evaluated. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Tumor and germline profiles were analyzed for pathogenic and likely pathogenic ("pathogenic") variants in 60 moderate- or high-penetrance genes associated with cancer predisposition. The germline probability (germline/germline + somatic) of a variant was calculated for each gene. Clinical and pathologic factors were analyzed as potential modifiers of germline probability. RESULTS AND LIMITATIONS: Of the 1883 patients identified, 1084 (58%) had a somatic or germline pathogenic variant in one of 60 cancer susceptibility genes, and of them, 240 (22%) had at least one germline variant. Overall, the most frequent variants were in TP53, PTEN, APC, BRCA2, RB1, ATM, and CHEK2. Variants in TP53, PTEN, or RB1 were identified in 746 (40%) patients and were exclusively somatic. Variants with the highest germline probabilities were in PALB2 (69%), MITF (62%), HOXB13 (60%), CHEK2 (55%), BRCA1 (55%), and BRCA2 (47%), and the overall germline probability of a variant in any DNA damage repair gene was 40%. Limitations were that most of the men included in the cohort had metastatic disease, and different thresholds for pathogenicity exist for somatic and germline variants. CONCLUSIONS: Of patients with pathogenic variants found on prostate tumor sequencing, 22% had clinically actionable germline variants, for which the germline probabilities varied widely by gene. Our results provide an evidenced-based clinical framework to prioritize referral to genetic counseling following tumor-only sequencing. PATIENT SUMMARY: Patients with advanced prostate cancer are recommended to have germline genetic testing. Genetic sequencing of a patient's prostate tumor may also identify certain gene variants that are inherited. We found that patients who had variants in certain genes, such as ones that function in DNA damage repair, identified in their prostate tumor sequencing, had a high risk for having an inherited cancer syndrome.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Truong H, Breen K, Nandakumar S, et al. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer. Eur Urol. 2022. PMID: 36115772. doi:10.1016/j.eururo.2022.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。